Form PRE 14A - Other preliminary proxy statements

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No. )

Filed by the registrant ☒
Filed by a party other than the Registrant ☐

Check the appropriate box:

☒

Preliminary Proxy Statement

☐

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐

Definitive Proxy Statement

☐

Definitive Additional Materials

☐

Soliciting Material under § 240.14a-12

ADC Therapeutics SA
(Name of registrant as specified in its charter)
(Name of person(s) filing proxy statement, if other than the registrant)

Payment of Filing Fee (Check all boxes that apply):

☒

No fee required

☐

Fee paid previously with preliminary materials

☐

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

ADC Therapeutics SA
Biopôle, Route de la Corniche 3B
1066 Epalinges
Switzerland

NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

Date and Time: November 11, 2024 at 10:00 AM EST / 4:00 PM CET
Location: Biopôle, Route de la Corniche 3B, 1066 Epalinges, Switzerland

Dear Shareholders:

We are pleased to invite you to an extraordinary general meeting of shareholders (the “Special Meeting”) of ADC Therapeutics SA (the “Company”) to be held on November 11, 2024 at 10:00 AM EST / 4:00 PM CET at the Company’s headquarters located at Biopôle, Route de la Corniche 3B, 1066 Epalinges, Switzerland.

At the Special Meeting, shareholders will be asked to consider and vote upon the following matters, which are discussed in greater detail in the accompanying proxy statement:

Approving amendments to Article 4a of the articles of association to increase the Company’s capital range.

Approving amendments to Article 4c of the articles of association to increase the Company’s conditional share capital for financing, acquisitions and other purposes.

We will also consider and act upon any other matters that properly come before the Special Meeting or any adjournment or postponement thereof.

Only shareholders of record at the close of business on September 20, 2024 are entitled to notice of and vote at the Special Meeting or any postponement(s) or adjournment(s) of the Special Meeting.

Under U.S. Securities and Exchange Commission (“SEC”) rules that allow companies to furnish proxy materials to shareholders over the Internet, we have elected to make our proxy materials available to all of our shareholders over the Internet. We will be able to provide shareholders with the information they need, while at the same time conserving natural resources and lowering the cost of delivery. On or about , 2024, we will commence sending to our shareholders a Notice of Internet Availability of Proxy Materials (the “Notice”) containing instructions on how to access our proxy statement for the Special Meeting. The Notice also provides instructions on how to vote online or vote by phone and includes instructions on how to receive a paper copy of the proxy materials by mail.

Whether or not you plan to attend the Special Meeting, it is important that you cast your vote. You may vote over the Internet, by telephone or by mail. You are urged to vote in accordance with the instructions set forth in the accompanying proxy statement. We encourage you to vote by proxy so that your shares will be represented and voted at the Special Meeting, whether or not you can attend.

Thank you for your ongoing support of and interest in ADC Therapeutics SA.

By order of the board of directors,

/s/ Ron Squarer
Chair of the board of directors

/s/ Peter J. Graham
Secretary

TABLE OF CONTENTS

INFORMATION ABOUT THE SPECIAL MEETING	2
PROPOSAL NO. 1: APPROVING AMENDMENTS TO ARTICLE 4A OF THE ARTICLES OF ASSOCIATION TO INCREASE THE COMPANY’S CAPITAL RANGE	7
PROPOSAL NO. 2: APPROVING AMENDMENTS TO ARTICLE 4C OF THE ARTICLES OF ASSOCIATION TO INCREASE THE COMPANY’S CONDITIONAL SHARE CAPITAL FOR FINANCING, ACQUISITIONS AND OTHER PURPOSES	10
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT	13
OTHER MATTERS	15

PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION

ADC Therapeutics SA
Biopôle, Route de la Corniche 3B
1066 Epalinges
Switzerland

PROXY STATEMENT
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

Date and Time: November 11, 2024 at 10:00 AM EST / 4:00 PM CET
Location: Biopôle, Route de la Corniche 3B, 1066 Epalinges, Switzerland

This proxy statement (this “Proxy Statement”) and Notice of Extraordinary General Meeting of Shareholders are being provided to you in connection with the solicitation of proxies by our board of directors for use at our extraordinary general meeting of shareholders (the “Special Meeting”) to be held on November 11, 2024 at 10:00 AM EST / 4:00 PM CET at the Company’s headquarters located at Biopôle, Route de la Corniche 3B, 1066 Epalinges, Switzerland.

Shareholders of record at the close of business on September 20, 2024 are invited to attend the Special Meeting and are entitled to vote on the proposals described in this Proxy Statement.

On or about , 2024, we made available this Proxy Statement and the attached Notice of Extraordinary General Meeting of Shareholders to all shareholders entitled to vote at the Special Meeting and we began sending the Notice Regarding the Availability of Proxy Materials to all shareholders entitled to vote at the Special Meeting.

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS
FOR THE EXTRAORDINARY MEETING OF SHAREHOLDERS
TO BE HELD ON NOVEMBER 11, 2024

This Proxy Statement is not a form for voting and presents only an overview of the proxy materials, which contain important information. You are encouraged to access and view the complete proxy materials before voting. This Proxy Statement and the proxy materials are available for viewing, printing and downloading at ir.adctherapeutics.com/sec-filings/annual-reports-and-proxies/default.aspx. Additionally, you can find a copy of this Proxy Statement on the website of the U.S. Securities and Exchange Commission (the “SEC”) at sec.gov. You may also obtain a printed copy of this Proxy Statement and the proxy materials, at no cost, upon written or oral request to us at the following address: Investor Relations, ADC Therapeutics SA, c/o ADC Therapeutics America, Inc., 430 Mountain Avenue, 4th Floor, Murray Hill, NJ 07974; (908) 731-5556.

INFORMATION ABOUT THE SPECIAL MEETING

Why am I receiving this Proxy Statement?

ADC Therapeutics SA (the “Company”) is soliciting proxies for the Special Meeting. You are receiving this Proxy Statement because you owned common shares of the Company at the close of business on September 20, 2024, the record date for the Special Meeting, which entitles you to vote at the Special Meeting unless you dispose of your shares or otherwise cease to have voting rights in relation to your shares before the Special Meeting. By use of a proxy, you can vote whether or not you attend the Special Meeting. This Proxy Statement describes the matters on which we would like you to vote and provides information on such matters so that you can make an informed decision.

When and where is the Special Meeting?

The Special Meeting is scheduled to be held on November 11, 2024 at 10:00 AM EST / 4:00 PM CET at the Company’s headquarters located at Biopôle, Route de la Corniche 3B, 1066 Epalinges, Switzerland.

What is the purpose of the Special Meeting?

At the Special Meeting, shareholders will be asked to consider and vote upon the following matters:

Approving amendments to Article 4a of the articles of association to increase the Company’s capital range.

Approving amendments to Article 4c of the articles of association to increase the Company’s conditional share capital for financing, acquisitions and other purposes.

We will also consider and act upon any other matters that properly come before the Special Meeting or any adjournment or postponement thereof. If any other matter properly comes before the shareholders for a vote at the Special Meeting, unless the shareholder elected otherwise in its instructions to the Independent Proxy, the Independent Proxy will have authority to vote the proxy on such matters in accordance with the recommendation of the board of directors.

Why did I receive a notice in the mail regarding the Internet availability of proxy materials instead of a full set of proxy materials?

In accordance with SEC rules, we are permitted to furnish proxy materials to our shareholders by providing access to such documents on the Internet instead of mailing printed copies. If you received a Notice of Internet Availability of Proxy Materials (the “Notice”) by mail, you will not receive a printed copy of the proxy materials. Most shareholders will not receive printed copies of the proxy materials unless they request them. Instead, the Notice, which was mailed to our shareholders, will instruct you as to how you may access and review all of the proxy materials on the Internet. The Notice also instructs you as to how you may submit your proxy on the Internet. If you would like to receive a paper copy of the proxy materials, you should follow the instructions for requesting such materials in the Notice.

When is the record date for the Special Meeting?

The record date for the meeting is September 20, 2024. Only shareholders of record at the close of business on that date are entitled to vote at the meeting (unless they dispose of their shares before the Special Meeting). No shareholders will be registered in the share register, and will thus become shareholders of record, between the record date and the date of the Special Meeting.

Will I be able to vote if I sell my shares after the record date?

Only shareholders of record at the close of business on the record date are entitled to vote at the Special Meeting. Shareholders who sell their shares prior to the Special Meeting will not be able to vote even if they are in possession of the proxy materials.

How many shares were outstanding as of the record date?

At the close of business on the record date, there were common shares outstanding. The number of common shares that will be entitled to vote at the Special Meeting will vary depending on how many common shares are deregistered between the record date and the date of the Special Meeting.

To how many votes am I entitled?

Each common share is entitled to one vote per share on all matters presented for a vote. However, our articles of association provide that, if an individual or legal entity acquires shares and, as a result, directly or indirectly, has (alone or in concert with other parties) voting rights with respect to more than 15% of the share capital recorded in the Commercial Register, the shares exceeding the 15% limit shall be entered in the share register as shares without voting rights. If shares are being held by a nominee for third-party beneficiaries that control (alone or together with third parties) voting rights with respect to more than 15% of the share capital, the board of directors may cancel the registration of the shares with voting rights held by such nominee in excess of the 15% limit.

What is the difference between being a shareholder of record and a beneficial owner?

Many of our shareholders hold their shares through brokers, banks or other nominees, rather than directly in their own names. As summarized below, there are some differences between being a shareholder of record and a beneficial owner.

Shareholder of Record: If your shares are registered directly in your name with our transfer agent, Computershare Trust Company, N.A. (“Computershare”), you are the shareholder of record, and these proxy materials are being sent directly to you. As the shareholder of record, you have the right to grant your voting proxy directly to the individuals named on the proxy card and to attend and vote at the Special Meeting.

Beneficial Owner: If your shares are held in a stock brokerage account or by a bank or other nominee, you are the beneficial owner of shares held in “street name,” and these proxy materials are being forwarded to you by your broker, bank or other nominee, who is considered to be the shareholder of record. As the beneficial owner, you have the right to tell your nominee how to vote, and you are also invited to attend the Special Meeting. However, since you are not the shareholder of record, you may not vote your shares at the Special Meeting unless you obtain a legal proxy from your broker, bank or nominee authorizing you to do so. Your nominee has sent you instructions on how to direct the nominee’s vote in advance of the meeting through the voting instruction card. You may vote by following those instructions.

I share an address with another shareholder. What do I do if we received only one paper copy of the proxy materials and want additional copies, or we received multiple copies and want only one?

SEC rules permit companies and intermediaries, such as brokers and banks, to satisfy proxy statement delivery requirements for two or more shareholders sharing an address by delivering one proxy statement to those shareholders. This procedure, known as “householding,” reduces the amount of duplicate information that shareholders receive and lowers our printing and mailing costs. Shareholders who participate in householding will continue to be able to access and receive separate proxy cards. Upon written or oral request, we will promptly deliver a separate copy of the Notice and, if applicable, the proxy materials to any shareholder of record at a shared address to which we delivered a single copy of any of these materials. To receive a separate copy, such shareholder of record may contact Investor Relations, ADC Therapeutics SA, c/o ADC Therapeutics America, Inc. 430 Mountain Avenue, 4th Floor, Murray Hill, NJ 07974 or by calling (908) 731-5556. Beneficial holders may contact their bank, brokerage firm, or other nominee to request information about householding.

Conversely, if shareholders of record living at the same address received multiple copies of the Notice and, if applicable, the proxy materials, you may request delivery of a single copy by contacting us as set forth above. Beneficial holders may contact their bank, brokerage firm, or other nominee to request a single copy of the Notice and, if applicable, the proxy materials.

How is a quorum reached?

There is no quorum requirement for the Special Meeting. Under Swiss law, corporations do not have specific quorum requirements for shareholder meetings, and our articles of association do not otherwise provide for a quorum requirement.

Who is the independent voting representative for the Special Meeting and how do I get in touch?

Swiss law requires public companies to appoint an independent voting representative (the “Independent Proxy”), to whom shareholders of record and nominees can give a proxy to vote on their behalf as well as voting instructions. The Company’s Independent Proxy is PHC Notaires, in Lausanne, Switzerland. You may contact the Independent Proxy at PHC Notaires, Pl. Benjamin-Constant 2, Case postale 1269, 1001 Lausanne, Switzerland.

Will representatives of the Company’s independent registered public accounting firm be present at the Special Meeting?

Representatives of PricewaterhouseCoopers SA are expected to be present at the Special Meeting, will have the opportunity to make a statement if they desire to do so and are expected to be available to respond to appropriate questions from shareholders at the Special Meeting.

How can I vote my shares in advance of the Special Meeting?

Whether you hold shares directly as the shareholder of record or beneficially in street name, you may direct how your shares are voted without attending the Special Meeting.

If you are a shareholder of record, you may vote by giving voting instructions and authorization to the Independent Proxy electronically through the Computershare portal with the individual shareholder number (QR Code). To do so, shareholders of record should follow the instructions given in the Notice. Shareholders of record may also give voting instructions and authorization to the Independent Proxy through Computershare by mail, using a proxy card.

If you are a beneficial owner, you may vote by giving voting instructions and authorization to the Independent Proxy electronically pursuant to the instructions of your broker or nominee and should use the portal designated by your broker or nominee. Beneficial owners should observe the deadlines to submit voting instructions and authorizations that are set in the instructions of their broker or nominee.

Can I attend the Special Meeting in person?

If you are a shareholder of record, or if you are a beneficial owner and have obtained a legal proxy from your broker, bank or nominee authorizing you to vote at the Special Meeting, you may attend the Special Meeting in person or arrange to be represented by another person with the right to vote. We recommend that you give voting instructions and authorization to the Independent Proxy even if you plan to attend the Special Meeting in person.

Shareholders who plan to attend the Special Meeting in person need to present their proxy card, a valid government-issued proof of identity and evidence of share ownership, such as the most recent account statement, at the Special Meeting venue. Such shareholders are urged to arrive at the Special Meeting venue no later than 10:00 AM EST / 4:00 PM CET on November 11, 2024.

To enable us to determine attendance correctly, shareholders leaving the Special Meeting early or temporarily will be requested to present their proxy card upon exit.

Can I revoke my proxy and change my vote?

You may revoke your proxy by notifying the Independent Proxy in writing, by returning a signed proxy with a later date, by transmitting a subsequent vote over the Internet or by telephone, or by attending the meeting and voting in person. If you choose to revoke your proxy by notifying the Independent Proxy or by returning a signed proxy with a later date, you must ensure that such action is taken and any notices or documents are received no later than November 4, 2024, 11:59 PM EST / November 5, 2024 at 5:59 AM CET. If you choose to revoke your proxy by transmitting a subsequent vote over the Internet or by telephone, you must do so prior to the close of the Internet

voting facility or the telephone voting facility at November 6, 2024, 11:59 PM EST / November 7, 2024 at 5:59 AM CET. If your shares are held in street name, you must contact your broker or nominee for instructions as to how to change your vote.

What if I do not vote my shares?

If you are a shareholder of record, if you do not vote or give instructions to the Independent Proxy to vote, your shares will not be counted for or against the proposals.

If you are a beneficial owner, if you do not vote or give instructions to the Independent Proxy to vote via your broker or nominee, then under applicable rules, your broker or nominee will still be able to vote your shares with respect to certain “routine” items. Proposal #1 (approving amendments to Article 4a of the articles of association to increase the Company’s capital range) and Proposal #2 (approving amendments to Article 4c of the articles of association to increase the Company’s conditional share capital for financing, acquisitions and other purposes) are considered routine items. Accordingly, your broker may vote your shares in its discretion with respect to these proposals even if you do not give voting instructions. We encourage you to give your broker or nominee voting instructions with respect to all proposals.

How does the board of directors recommend I vote on the proposals?

The board of directors recommends that you vote “FOR” Proposal #1 (approving amendments to Article 4a of the articles of association to increase the Company’s capital range) and “FOR” Proposal #2 (approving amendments to Article 4c of the articles of association to increase the Company’s conditional share capital for financing, acquisitions and other purposes).

What is the vote required to approve the proposals and how are votes counted?

The affirmative vote of two-thirds of votes represented and the majority of the par value of the shares represented at the Special Meeting is required for Proposal #1 (approving amendments to Article 4a of the articles of association to increase the Company’s capital range) and for Proposal #2 (approving amendments to Article 4c of the articles of association to increase the Company’s conditional share capital for financing, acquisitions and other purposes). Abstentions will have the same effect as votes “AGAINST” these proposals. We do not expect any broker non-votes for these proposals. Please refer to “What if I do not vote my shares?” regarding brokers’ ability to vote your shares with respect to routine items.

Are there other matters to be voted on at the Special Meeting?

We do not know of any matters that may come before the Special Meeting other than the proposals set forth in this Proxy Statement. If any other matters are properly presented at the Special Meeting, unless the shareholder elected otherwise in its instructions to the Independent Proxy, the Independent Proxy will have authority to vote the proxy on such matters in accordance with the recommendation of the board of directors.

How are proxies solicited for the Special Meeting and who is paying for such solicitation?

The board of directors is soliciting proxies for use at the Special Meeting by means of the proxy materials. We will bear the entire cost of proxy solicitation, including the preparation, assembly, printing, mailing and distribution of the proxy materials. Copies of solicitation materials will also be made available upon request to brokers, banks and other nominees to forward to the beneficial owners of the shares held of record by such brokers, banks or other nominees. The original solicitation of proxies may be supplemented by solicitation by telephone, electronic communication, or other means by our directors, officers or employees. No additional compensation will be paid to these individuals for any such services, although we may reimburse such individuals for their reasonable out-of-pocket expenses in connection with such solicitation. We have retained Alliance Advisors, LLC as proxy solicitor to assist in the solicitation of proxies for $16,000.

If you choose to access the proxy materials and/or vote over the Internet, you are responsible for Internet access charges you may incur. If you choose to vote by telephone, you are responsible for telephone charges you may incur.

How can I find out the results of the voting at the Special Meeting?

Final voting results will be contained in a Current Report on Form 8-K that will be filed within four business days after the Special Meeting.

Who should I call if I have any additional questions?

If you are a shareholder of record, you may contact Investor Relations, ADC Therapeutics SA, c/o ADC Therapeutics America, Inc. 430 Mountain Avenue, 4th Floor, Murray Hill, NJ 07974 or by calling (908) 731-5556. If you are a beneficial owner, please contact the telephone number provided on your voting instruction form or contact your broker or nominee holder directly.

What is the mailing address of the Company’s principal executive office?

The mailing address of our principal executive office is Biopôle, Route de la Corniche 3B, 1066 Epalinges, Switzerland.

PROPOSAL NO. 1: APPROVING AMENDMENTS TO ARTICLE 4A OF THE ARTICLES OF ASSOCIATION TO INCREASE THE COMPANY’S CAPITAL RANGE

Explanation

Background and Reasons for the Proposal

Shareholders of a Swiss corporation cannot give the board of directors blanket authorization to issue new shares. However, under Swiss law, companies may have a so-called capital range, under which the board of directors is authorized to increase and/or decrease the share capital by up to 50% each during a period of up to 5 years.

At our annual general meeting of shareholders held on June 14, 2023, our shareholders adopted such a capital range, ranging from CHF 7,123,355.68 (lower limit) to CHF 10,685,033.52 (upper limit), in article 4a of our articles of association. Under that capital range, the board of directors is authorized within the capital range to increase or reduce the share capital once or several times and in any amounts or to acquire or dispose of shares directly or indirectly, until June 14, 2028 or until an earlier expiry of the capital range. The capital increase or reduction may be effected by issuing up to 44,520,973 fully paid-in registered shares with a par value of CHF 0.08 each and cancelling up to 44,520,973 registered shares with a par value of CHF 0.08 each, as applicable, or by increasing or reducing the par value of the existing shares within the limits of the capital range or by simultaneous reduction and re-increase of the share capital.

On the date of our annual general meeting of shareholders held on June 14, 2023, we had 89,041,946 common shares in issue. At that time, the upper limit of our capital range was at the maximum allowed by Swiss law, namely 150% of our share capital at that time. Since then, we issued 10,411,912 shares out of the capital range in an underwritten offering in May 2024. Accordingly, the board of directors proposes to amend article 4a para. 1 of the articles of association to increase the upper and lower limit of the capital range to one ranging from CHF 7,956,308.64 (lower limit) to CHF 11,934,462.96 (upper limit). The proposed lower limit is equal to our current share capital, which means that our board of directors would not be authorized to reduce the Company’s share capital to a level below our current share capital. The proposed upper limit corresponds to 150% of our current share capital, which is the maximum allowed by Swiss law.

In addition, the board of directors proposes to strike the number of shares that may be issued or canceled within the capital range, as this information is no longer required to be included in our articles of association according to Swiss legal practice. The number of shares that the board of directors may issue or cancel continues to be determined by the upper and the lower limit of the capital range as compared to the number of shares in issue at any point in time.

As is the case under the current capital range, the board of directors has the right to restrict or withdraw shareholders’ pre-emptive rights in the event of an issue of shares within the capital range. The reasons for the restriction or withdrawal of pre-emptive rights remain the same as under the current capital range.

We have incurred substantial net losses since our inception, expect to continue to incur losses for the foreseeable future. Accordingly, we may need to raise additional capital to fund our operations and execute our business plan. The proposed amendments to the articles of association would allow us to raise additional capital through the sale of our securities to fund our operations and execute our business plan. In addition to financing activities, we would benefit from deploying our share capital as we pursue strategic licensing transactions, collaborations and acquisitions.

Approval of this proposal does not mean that the maximum number of shares authorized to be issued under the capital range will, in fact, be issued. Rather, approval of this proposal gives the board of directors, in its discretion, the ability to raise additional funds to fund our operations and execute our business plan.

We have no current plans, agreements, arrangements or understandings relating to the issuance of the additional common shares from the capital range that will become available as a result of the proposed amendments to the articles of association.

Text of the Proposed Amendments

If this proposal is approved, article 4a, para. 1 of the articles of association will be amended to reflect the foregoing as follows (red strikethrough text represents deletions and blue underlined text represents additions):

English version		French version
Capital Range	¹The Company has a capital range ranging from CHF ~~7,123,355.68~~ 7,956,308.64 (lower limit) to CHF ~~10,685,033.52~~ 11,934,462.96 (upper limit). The Board of Directors shall be authorized within the capital range to increase or reduce the share capital once or several times and in any amounts or to acquire or dispose of shares directly or indirectly, until ~~June 14, 2028~~ November 11, 2029 or until an earlier expiry of the capital range. The capital increase or reduction may be effected by issuing ~~up to 44,520,973~~ fully paid-in registered shares with a par value of CHF 0.08 each and cancelling ~~up to 44,520,973~~ registered shares with a par value of CHF 0.08 each, as applicable, or by increasing or reducing the par value of the existing shares within the limits of the capital range or by simultaneous reduction and re-increase of the share capital.	Marge de fluctuation du capital	¹La Société dispose d'une marge de fluctuation du capital allant de CHF ~~7'123'355.68~~ 7'956'308.64 (limite inférieure) à CHF ~~10'685'033.52~~ 11'934'462.96 (limite supérieure). Le Conseil d'administration peut, dans les limites définies de la marge de fluctuation, et ce jusqu'au ~~14 juin 2028~~ 11 Novembre 2029 ou jusqu'à l'expiration anticipée de la marge de fluctuation, augmenter ou réduire le capital-actions en une ou plusieurs fois, de quelque montant que ce soit, ou acquérir ou aliéner des actions directement ou indirectement. L'augmentation ou la réduction du capital peut se faire par l'émission ~~de jusqu'à 44'520'973~~ d’actions nominatives d'une valeur nominale de CHF 0.08 chacune, qui doivent être intégralement libérées, respectivement l'annulation ~~de jusqu'à 44'520'973~~ d’actions nominatives d'une valeur nominale de CHF 0.08 chacune, ou par une augmentation ou une réduction, dans les limites de la marge de fluctuation, de la valeur nominale des actions nominatives existantes ou encore par une réduction et une nouvelle augmentation simultanées.

Anti-Takeover Effects of the Proposal

Release No. 34-15230 of the SEC Staff requires disclosure and discussion of the effects of any action that may be used as an anti-takeover mechanism. Because the proposed amendments to the articles of association will result in an increase in the capital range, this proposal could, under certain circumstances, have an anti-takeover effect, although this is not the purpose or intent of the board of directors. An increase in the capital range could enable the board of directors to render more difficult or discourage an attempt by a party attempting to obtain control of us by tender offer or other means. The use of the capital range to issue common shares or securities convertible into or exercisable for common shares in a public or private sale, merger or similar transaction would increase the number of outstanding shares entitled to vote, increase the number of votes required to approve a change of control of us and dilute the interest of a party attempting to obtain control of us. Any such issuance could deprive shareholders of benefits that could result from an attempt to obtain control of the Company, such as the realization of a premium over the market price that such an attempt could cause. Moreover, the issuance of common shares or securities convertible into or exercisable for common shares to persons friendly to the board of directors could make it more

difficult to remove incumbent officers and directors from office even if such change were favorable to shareholders generally.

As stated above, we have no present intent to use the increase in the capital range for anti-takeover purposes, and the proposed amendments to the articles of association are not part of a plan by the board of directors to adopt a series of anti-takeover provisions; however, if this proposal is approved by the shareholders, then a greater amount of common shares or other securities would be available for such purpose than is currently available. This proposal is not the result of any attempt to obtain control of us and the board of directors has no present intent to authorize the issuance of additional common shares or other securities to discourage any such efforts if they were to arise.

Dissenters’ Right of Appraisal

Under Swiss law, shareholders are not entitled to dissenters’ right of appraisal or similar right with respect to this proposal. We will not independently provide shareholders with any such right or similar right.

Interests of Certain Persons in the Proposal

Certain of our directors and executive officers have an interest in this proposal as a result of their ownership of our common shares, as set under “Security Ownership of Certain Beneficial Owners and Management.” However, we do not believe that our directors or executive officers have interests in this proposal that are different from or greater than those of any of our other shareholders.

Proposal

The board of directors proposes that the amendments to article 4a of the articles of association to increase the Company’s capital range be approved.

Voting Requirement

The affirmative vote of two-thirds of the votes represented and the majority of the par value of the shares represented at the Special Meeting is required for this proposal. Abstentions will have the same effect as votes “AGAINST” this proposal. This is a “routine” item and thus we do not expect any broker non-votes.

Recommendation

The board of directors recommends that you vote “FOR” this proposal.

PROPOSAL NO. 2: APPROVING AMENDMENTS TO ARTICLE 4C OF THE ARTICLES OF ASSOCIATION TO INCREASE THE COMPANY’S CONDITIONAL SHARE CAPITAL FOR FINANCING, ACQUISITIONS AND OTHER PURPOSES

Explanation

Background and Reasons for the Proposal

Swiss companies may have a so-called conditional share capital, under which new shares in the amount of up to 50% of the share capital can be issued through the exercise or mandatory exercise of equity-linked instruments issued by the board of directors. Our articles of association provide for (i) a conditional share capital for employee participation and (ii) a conditional share capital for financing, acquisitions and other purposes, both of which set forth the maximum number of new common shares that the board of directors is authorized to use as underlying such equity-linked instruments. Our conditional share capital for financing, acquisitions and other purposes (article 4c of our articles of association) authorizes our board of directors to issue a certain number of common shares through the exercise or mandatory exercise of conversion, exchange, option, warrant or similar rights or obligations for the subscription of common shares granted to shareholders or third parties on a stand-alone basis or in connection with bonds, notes, options, warrants or other securities or contractual obligations of the Company or any of its group companies, including, without limitation, convertible debentures (collectively, the “Financial Instruments”).

At the time of our initial public offering in May 2020, our articles of association provided for a conditional share capital for financing, acquisitions and other purposes that authorized the board of directors to issue up to 20,300,000 common shares pursuant to article 4c of our articles of association. As of the date of our annual general meeting of shareholders held on June 13, 2024, we had reserved 13,103,400 common shares out of the remaining 17,909,703 common shares still available under this conditional share capital. Given the limited number of common shares still available under this conditional share capital, the board of directors proposes to amend article 4c para. 1 of the articles of association to increase the number of common shares issuable under this conditional share capital to the maximum number permissible under Swiss law, being 50% of our share capital, minus the number of common shares issuable under our conditional share capital for employee participation.

As is the case under the current conditional share capital for financing, acquisitions and other purposes, the board of directors has the right to restrict or withdraw shareholders’ pre-emptive rights in the event of an issue of Financial Instruments using this conditional share capital. The reasons for the restriction or withdrawal of pre-emptive rights remain the same as under the current conditional share capital for financing, acquisitions and other purposes.

We have incurred substantial net losses since our inception, expect to continue to incur losses for the foreseeable future. Accordingly, we may need to raise additional capital to fund our operations and execute our business plan. The proposed amendments to the articles of association would allow us to raise additional capital through the sale of securities convertible into or exercisable for our common shares or similar Financial Instruments to fund our operations and execute our business plan. In addition to financing activities, we would benefit from deploying our conditional share capital for financing, acquisitions and other purposes such as optimizing our capital structure, as we pursue strategic licensing transactions, collaborations, acquisitions and other strategic transactions.

If this proposal is approved, except as required under NYSE listing standards, no further authorization from shareholders will be necessary or solicited prior to an issuance of Financial Instruments or common shares upon the conversion or exercise of Financial Instruments under the conditional share capital for financing, acquisitions and other purposes. The terms of any such Financial Instruments, including dividend or interest rates, conversion prices, voting rights, redemption prices, maturity dates and similar matters, will be determined by our board of directors.

Approval of this proposal does not mean that the maximum number of shares authorized to be issued under the conditional share capital for financing, acquisitions and other purposes provision will, in fact, be issued. Rather, approval of this proposal gives the board of directors, in its discretion, the ability to raise additional funds to fund our operations and execute our business plan.

We have no current plans, agreements, arrangements or understandings relating to the issuance of additional Financial Instruments convertible into or exercisable for the additional common shares that would be available under

the conditional share capital for financing, acquisitions and other purposes if our shareholders approve the proposed amendments to the articles of association, which would result in an increase in the aggregate number of outstanding common shares and common shares issuable upon the conversion or exercise of Financial Instruments.

Text of the Proposed Amendments

If this proposal is approved, article 4c, para. 1 of the articles of association will be amended to reflect the foregoing as follows (red strikethrough text represents deletions and blue underlined text represents additions):

English version		French version
Conditional Share Capital for Financing, Acquisitions and other Purposes	¹The share capital may be increased including in connection with an intended takeover in an amount not to exceed CHF ~~1,432,776.24~~ 3,042,154.32 through the issuance of up to ~~17,909,703~~ 38,026,929 fully paid in registered shares with a par value of CHF 0.08 per share through the exercise or mandatory exercise of conversion, exchange, option, warrant or similar rights or obligations for the subscription of shares granted to shareholders or third parties on a stand-alone basis or in connection with bonds, notes, options, warrants or other securities or contractual obligations of the Company or any of its group companies, including without limitation a convertible debenture to be entered into by the Company, as may be amended or novated from time to time (hereinafter collectively, the Financial Instruments).	Capital-actions conditionnel aux fins de financement, acquisitions ou d'autres buts	¹Le capital-actions peut être augmenté, y compris en lien avec une future offre publique d'acquisition, d'un montant maximum de CHF ~~1'432'776.24~~ 3'042'154.32 par l'émission de ~~17'909'703~~ 38'026'929 actions nominatives au plus, d'une valeur nominale de CHF 0.08 chacune, qui doivent être intégralement libérées par l'exercice ou l'exercice obligatoire de droits de conversion, d'échange, d'option, de warrant ou d'autres droits ou obligations similaires pour la souscription d'actions octroyés aux actionnaires ou à des tiers de manière autonome ou en rapport avec des obligations, effets, options, warrants ou autres instruments financiers ou obligations contractuelles de la Société ou de l'une des sociétés du groupe, y compris, mais sans s'y limiter, une débenture convertible de la société, laquelle peut être amenée à être modifiée ou actualisée (ci-après désignés collectivement les Instruments Financiers).

Anti-Takeover Effects of the Proposal

Release No. 34-15230 of the SEC Staff requires disclosure and discussion of the effects of any action that may be used as an anti-takeover mechanism. Because the proposed amendments to the articles of association will result in an increase in conditional share capital for financing, acquisitions and other purposes, this proposal could, under certain circumstances, have an anti-takeover effect, although this is not the purpose or intent of the board of directors. An increase in conditional share capital for financing, acquisitions and other purposes could enable the board of directors to render more difficult or discourage an attempt by a party attempting to obtain control of us by tender offer or other means. The use of conditional share capital for financing, acquisitions and other purposes to issue securities convertible into or exercisable for the additional common shares in a public or private sale, merger or similar transaction would increase the number of outstanding shares entitled to vote, increase the number of votes required to approve a change of control of us and dilute the interest of a party attempting to obtain control of us. Any such issuance could deprive shareholders of benefits that could result from an attempt to obtain control of the Company, such as the realization of a premium over the market price that such an attempt could cause. Moreover, the issuance of securities convertible into or exercisable for common shares to persons friendly to the board of directors could make it more difficult to remove incumbent officers and directors from office even if such change were favorable to shareholders generally.

As stated above, we have no present intent to use the increase in the conditional share capital for financing, acquisitions and other purposes for anti-takeover purposes, and the proposed amendments to the articles of association are not part of a plan by the board of directors to adopt a series of anti-takeover provisions; however, if this proposal is approved by the shareholders, then a greater amount of common shares or other securities would be available for such purpose than is currently available. This proposal is not the result of any attempt to obtain control of us and the board of directors has no present intent to authorize the issuance of securities convertible into or exercisable for the additional common shares to discourage any such efforts if they were to arise.

Dissenters’ Right of Appraisal

Interests of Certain Persons in the Proposal

Proposal

The board of directors proposes that the amendments to article 4c of the articles of association to increase the Company’s conditional share capital for financing, acquisitions and other purposes be approved.

Voting Requirement

Recommendation

The board of directors recommends that you vote “FOR” this proposal.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table presents information relating to the beneficial ownership of our common shares as of September 1, 2024:

each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding common shares;

each of our executive officers and directors; and

all executive officers and directors as a group.

The number of common shares beneficially owned by each entity, person, executive officer or director is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any common shares over which the individual has sole or shared voting power or investment power as well as any common shares that the individual has the right to acquire within 60 days from September 1, 2024 through the exercise of any option or other right. Except as otherwise indicated, and subject to applicable community property laws, we believe that the persons named in the table have sole voting and investment power.

The percentage of outstanding common shares beneficially owned is computed based on 96,666,748 common shares outstanding as of September 1, 2024. Common shares that a person has the right to acquire within 60 days are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all executive officers and directors as a group. Unless otherwise indicated below, the business address for each beneficial owner is ADC Therapeutics SA, Biopôle, Route de la Corniche 3B, 1066 Epalinges, Switzerland.

Principal Shareholders	Number of Common Shares Beneficially Owned	Percentage of Common Shares Beneficially Owned
5% Shareholders
Redmile Group LLC ⁽¹⁾	15,269,217	15.8%
Dr. Hans-Peter Wild and entities affiliated with Dr. Hans-Peter Wild ⁽²⁾	9,788,944	10.1%
Prosight Management L.P. ⁽³⁾	9,570,000	9.9%
Executive Officers and Directors
Robert Azelby	23,338	*
Jean-Pierre Bizzari	56,904	*
Jose “Pepe” Carmona	210,833	*
Peter Hug	142,644	*
Ameet Mallik	991,845	1.0%
Viviane Monges	94,783	*
Thomas Pfisterer⁽⁴⁾	625,756	*
Tyrell J. Rivers ⁽⁵⁾	—	*
Victor Sandor	71,998	*
Ron Squarer ⁽⁶⁾	1,545,007	1.6%
Mohamed Zaki	233,333	*
All executive officers and directors as a group (11 persons)	3,996,441	4.1%

* Less than 1% of our total outstanding common shares.

(1)

This information is based on a Schedule 13F filed with the SEC on August 14, 2024 by Redmile Group, LLC. The common shares are owned by certain private investment vehicles and/or separately managed accounts managed by Redmile Group, LLC. The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or

separately managed accounts, as well as by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. The business address of each of Redmile Group, LLC and Mr. Green is One Letterman Drive, Building D, Suite D3-300, The Presidio of San Francisco, San Francisco, California 94129.

The number of common shares beneficially owned by Redmile Group, LLC excludes 8,163,265 common shares issuable upon the exercise of pre-funded warrants, as such warrants include a provision that a holder is prohibited from exercising such warrants to the extent that, upon such exercise, the number of common shares then beneficially owned by the exercising holder and its affiliates and any other person or entity with whom the exercising holder’s beneficial ownership would be aggregated for purposes of Section 13(d) under the Exchange Act, would exceed 9.99% of the total number of common shares outstanding immediately after giving effect to such exercise.

(2)

Dr. Hans-Peter Wild holds a portion of the shares directly and the other portion indirectly via HP WILD Holding AG (“HPW Holding”) and HPWH TH AG (“HPWH”). The principal business of HPWH is holding investment rights in, directly or indirectly, ADC Therapeutics. HPW Holding is an intermediary holding company. Dr. Hans-Peter Wild is the chairman of HPWH and HPW Holding.

(3)

This information is based on a Schedule 13F filed with the SEC on August 14, 2024 by Prosight Management, LP. The business address of each of the foregoing persons and entities is c/o Prosight Management, LP, 5956 Sherry Lane, Suite 1365, Dallas, Texas 75225.

(4)

Thomas Pfisterer holds a portion of the shares directly and the other portion indirectly via HPWH TH AG (“HPWH”) and HPWH MH AG (“MH”). The principal business of HPWH is holding investment rights in, directly or indirectly, ADC Therapeutics. HP WILD Holding AG (“HPW Holding”) is an intermediary holding company. Thomas Pfisterer is a board member of HPWH. By reason of a stockholders’ agreement by and among Mr. Pfisterer and HPW Holding and their joint indirect minority equity interest in HPWH via their joint ownership of MH, which owns a 12.5% interest in HPWH, Mr. Pfisterer may be deemed to have shared voting and investment power with respect to such shares held of record by HPWH. However, Mr. Pfisterer disclaims beneficial ownership of all common shares held of record by HPWH other than the shares indirectly represented by his 41.7% interest in MH.

(5)

Mr. Rivers, an executive director within AstraZeneca’s corporate development group, disclaims beneficial ownership with respect to common shares held of record by AstraZeneca.

(6)

Includes 159,026 shares held by a trust in which Mr. Squarer serves as a settlor and trustee.

OTHER MATTERS

Other Business at the Special Meeting

As of the date of this Proxy Statement, we know of no other business that will be conducted at the Special Meeting other than as described in this Proxy Statement. If any other matter or matters are properly brought before the Special Meeting or any adjournment or postponement of the Special Meeting, unless the shareholder elected otherwise in its instructions to the Independent Proxy, the Independent Proxy will have authority to vote the proxy on such matters in accordance with the recommendation of the board of directors.

Availability of Proxy Materials

This Proxy Statement is posted on the Investors section of our website adctherapeutics.com and is available from the SEC at its website at sec.gov. You may also obtain a printed copy of this Proxy Statement and the proxy materials, at no cost, upon written or oral request to us at the following address:

Investor Relations
ADC Therapeutics SA
c/o ADC Therapeutics America, Inc.
430 Mountain Avenue, 4th Floor
Murray Hill, NJ 07974
(908) 731-5556

Corporate Website

We maintain a website at adctherapeutics.com. Information contained on, or that can be accessed through, our website is not incorporated by reference into this Proxy Statement, and references to our website address in this Proxy Statement are inactive textual references only.

2025 Annual General Meeting of Shareholders

Shareholders wishing to present a proposal for inclusion in our proxy materials for the 2025 annual general meeting of shareholders pursuant to Rule 14a-8 of the Exchange Act must timely submit their proposals so that they are received by our Secretary at the address below no later than December 27, 2024 (120 calendar days prior to the anniversary of our mailing of the proxy statement for our 2024 annual general meeting of shareholders). The submission of a shareholder proposal does not guarantee that it will be included in our proxy statement and any such proposal must comply with the requirements of Rule 14a-8 in order to be considered for inclusion in our proxy materials for the 2025 annual general meeting of shareholders. Any communication to be made to our Secretary should be sent to ADC Therapeutics SA, c/o ADC Therapeutics America, Inc., 430 Mountain Avenue, 4th Floor, Murray Hill, NJ 07974, Attention: Secretary.

Shareholders who, alone or together, represent at least 0.5% of the share capital or voting rights may request that an item be included on the agenda of a meeting of shareholders or that a proposal with respect to an existing agenda item be included in the proxy statement for the 2025 annual general meeting of shareholders. Assuming the 2025 annual general meeting of shareholders is held in accordance with Swiss law on June 13, 2025, shareholders wishing to include an item on the agenda or a proposal with respect to an agenda item (including the nomination of a candidate for election to the board of directors) in the proxy statement for the 2025 annual general meeting of shareholders, other than pursuant to Rule 14a-8 of the Exchange Act, must submit a written notice so that it is received by our Secretary no later than March 17, 2025 (90 calendar days prior to the assumed date of the 2025 annual meeting of shareholders).

Any shareholder proposal or director nominations, including proposals pursuant to Rule 14a-8 of the Exchange Act, must comply with Swiss law and our articles of association.

To solicit proxies in support of director nominees other than the Company’s nominees, a shareholder must give timely notice that complies with the requirements of Rule 14a-19 and which must be received no later than April 14, 2025 (60 days prior to the anniversary of the 2024 annual general meeting of shareholders).